Enlicitide: The First PCSK9 Inhibitor Pill and What the Studies Showed

Key points

Enlicitide (brand name Lipfendra) is the first tablet in the class of PCSK9 inhibitors (proprotein convertase subtilisin/kexin type 9): the US Food and Drug Administration (FDA) approved it in July 2026, while earlier drugs of this class were given by injection. It is taken once daily, and in large studies it markedly lowered LDL cholesterol (low-density lipoprotein, "bad" cholesterol).

Why a pill is needed

Statins remain the foundation of treatment; if the effect is insufficient, ezetimibe or injectable PCSK9 inhibitors are added. Their use was limited by concerns about injections, cost, availability and "therapeutic inertia", when treatment is not intensified in time (Sun Y Drug Discov Ther 2026. PMID 42604807^[4]). A tablet removes the barrier of the injection, although it must be taken under special rules. In CORALreef Lipids it was added to ongoing treatment: 97 % of participants were taking statins (FDA prescribing information, 7/2026).

How it works

The liver removes LDL cholesterol from the blood with receptors on the surface of its cells. The PCSK9 protein binds to these receptors and promotes their breakdown. Enlicitide is a macrocyclic (ring-shaped) peptide: it prevents PCSK9 from binding to the receptor, more receptors remain, and they remove more LDL cholesterol from the blood (Sun Y Drug Discov Ther 2026. PMID 42604807^[4]).

The peptide is poorly absorbed when taken by mouth: even with sodium caprate, a substance added to the tablet to aid absorption, about 1 % of the dose reaches the blood. This is why the rules for taking it matter (FDA prescribing information, 7/2026).

What the studies showed

• Large study, 52 weeks. CORALreef Lipids enrolled 2,909 adults with a prior atherosclerotic cardiovascular disease (ASCVD) event or at increased risk of a first one; 2,904 received the drug or placebo. At 24 weeks LDL cholesterol on the drug fell by 57.1 % from baseline and rose by 3.0 % on placebo; the advantage of the drug persisted at week 52 (Navar AM N Engl J Med 2026. PMID 41879224^[1]).
• What this means in numbers. With a mean baseline LDL cholesterol of 2.5 mmol/L (96 mg/dL), a 57 % reduction brings it down to about 1.1 mmol/L (41 mg/dL); on placebo it stays at about 2.6 mmol/L (99 mg/dL) (rough conversion from the means in Navar AM N Engl J Med 2026. PMID 41879224^[1]).
• Heterozygous familial hypercholesterolemia. In CORALreef HeFH (heterozygous familial hypercholesterolemia, HeFH; 303 people; baseline LDL cholesterol 3.1 mmol/L (119 mg/dL), all taking statins) the difference from placebo was 59.4 percentage points at week 24 and 61.5 at week 52. Lipoprotein(a) fell by a median of 24.7 % over 24 weeks, and by 1.6 % on placebo (Ballantyne CM JAMA 2026. PMID 41206969^[2]).
• Dose selection. In phase 2b (380 people) the LDL cholesterol reduction grew with the dose: over 8 weeks the difference from placebo ranged from 41.2 (6 mg) to 60.9 percentage points (30 mg) (Ballantyne CM J Am Coll Cardiol 2023. PMID 36889610^[5]). The 20 mg dose gives almost the maximum reduction (FDA prescribing information, 7/2026).
• At different levels of risk. In 843 CORALreef Lipids participants without prior ASCVD events, LDL cholesterol fell by 57–63 percentage points more than on placebo in all four groups of 10-year risk by the PREVENT score (AHA 2026 abstracts, Navar AM).
• Two years. In the open-label extension (2,774 people from three CORALreef studies), the LDL cholesterol reduction, according to the authors, persisted up to week 104 (AHA 2026 abstracts, Ballantyne C).
• Tolerability. In both main studies, adverse events and discontinuations because of them occurred about as often as on placebo (Navar AM N Engl J Med 2026. PMID 41879224^[1]; FDA prescribing information, 7/2026). In heterozygous familial hypercholesterolemia, diarrhea (7 % vs 2 % on placebo) and dizziness (9 % vs 4 %) were more common (FDA prescribing information, 7/2026). In the extension, 1.6 % of participants stopped because of adverse events (AHA 2026 abstracts, Ballantyne C).

Who this pill is for

Per the FDA prescribing information, enlicitide is indicated for adults with elevated cholesterol, including familial hypercholesterolemia, to lower LDL cholesterol in addition to diet and physical activity. The studies enrolled people who needed to lower LDL cholesterol further despite statins: after a prior ASCVD event, at a level of 1.4 mmol/L (55 mg/dL) or higher; at risk of a first event, at 1.8 mmol/L (70 mg/dL) or higher (Navar AM N Engl J Med 2026. PMID 41879224^[1]; FDA prescribing information, 7/2026). Which level is the target for you is determined by your doctor.

What to do: how it is taken

The tablet is prescribed by a doctor, based on the lipid profile and overall cardiovascular risk. It supplements diet and physical activity and does not replace them. Per the FDA prescribing information:

• one 20 mg tablet once daily, in the morning on an empty stomach, with water (black coffee or unsweetened tea are allowed);
• swallow whole, do not break or chew;
• for at least 30 minutes after the dose, do not eat or drink anything except water, black coffee and unsweetened tea;
• take a missed dose as soon as possible, at least 30 minutes before the next meal; do not take two doses in one day;
• it can be combined with other drugs: no significant drug interactions were observed.

Taking it 30 minutes after a meal lowers the amount of drug in the blood by about half (by 48–50 %), so morning dosing on an empty stomach is part of the regimen. The LDL cholesterol reduction can be assessed as early as 4 weeks (FDA prescribing information, 7/2026).

Who should see a doctor first

Everyone: the regimen is chosen by the doctor based on a blood lipid test. Pregnant women and those planning pregnancy must tell their doctor: per the prescribing information, if pregnancy is detected the drug is stopped unless the benefit outweighs the possible risk to the fetus. Efficacy and safety in children have not been established. Statins and other prescribed drugs should not be stopped on your own.

Summary

Enlicitide is the first cholesterol pill with a PCSK9 inhibitor mechanism: in studies LDL cholesterol fell by 56–59 percentage points more than on placebo, and the drug was well tolerated. The goal of treatment is to lower LDL cholesterol; the effect on heart attacks and strokes is being studied. Whether the pill is right for you is decided by your doctor based on your tests. You can go over your lipid profile results at a consultation.